The global antibody production market size is expected to reach USD 37.81 Billion in 2030 and register a revenue CAGR of 14.4% over the forecast period, according to the latest report by Reports and Data. Rising prevalence of infectious and bacterial diseases, increased investment to accelerate the development of novel antibiotic therapies for infectious diseases, and an increasing number of R&D projects to discover and develop new antibiotics are expected to drive market revenue growth during the forecast period. Moreover, antibiotics are often used to avoid contamination in the manufacture of bacterial and viral vaccines, which is another significant reason expected to drive market revenue growth.
Antibodies are used to treat and prevent bacterial and infectious disorders in the healthcare business. Bactericidal drugs kill germs, but bacteriostatic medications inhibit bacteria from dividing and growing. Monoclonal antibodies (mAbs) are used to treat a variety of illnesses, including cancer, rheumatoid arthritis, and other chronic conditions. , While avoiding damage to non-target cells, targeted treatment is growing rapidly, because of its specificity for cancer cells. Targeted medicines are becoming increasingly popular as the incidence of cancer rises. Targeted antibodies are a type of cancer immunotherapy that works by disrupting cancer cell function and alerting the immune system to target and kill cancer cells.
Therapeutic monoclonal antibodies are the most rapidly growing class of novel therapeutic compounds. However, present manufacturing and purifying procedures limit therapeutic antibody production capacity, resulting in an increase in cost. In vivo genetics delivery of therapeutic monoclonal antibodies presents a novel potential answer to these challenges. Firstly, therapeutic effectiveness can be increased by maintaining stable therapeutic, non-toxic levels in the bloodstream for an incredibly long time. Repeated high-dose bolus injections might be avoided, lowering the risk of adverse effects. Secondly, the high cost of therapeutic antibody manufacture and purification might be decreased, making in vivo and ex vivo mAb gene transfer an economically realistic and attractive option.
In-depth Study of the Competitive Landscape:
The global Antibody Production market consists of various market players, which make this business sphere highly competitive. In this section of the report, the authors have provided authentic information on product portfolios, new product innovations, technological capabilities, and product pricing strategies of each of these players. Moreover, it discusses the key strategies implemented by these players, such as mergers & acquisitions, joint ventures, collaborations, partnerships and agreements, to build on their market presence.
Top companies profiled in the report include:
Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, AstraZeneca, AbbVie Inc., Pfizer Inc., Amgen Inc., and GlaxoSmithKline plc.
Key Market Regions Covered in the Report:
- North America (U.S., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- The Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Process Type Outlook (Revenue, USD Billion; 2019-2030)
- Upstream Processing
- Bioreactors
- Consumables
- Downstream Processing
- Chromatography System
- Chromatography Resins
- Filtration
- Filtration Systems
- Filtration Consumables & Accessories
Antibody Type Outlook (Revenue, USD Billion; 2019-2030)
- Monoclonal Antibodies (mAbs)
- Polyclonal Antibodies
- Other Antibodies
End-use Outlook (Revenue, USD Billion; 2019-2030)
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- Research Institutes
- Other End-use
Frequently asked questions addressed in the report:
- What is the revenue growth rate of the global Antibody Production market over the forecast period?
- What are the major factors driving the growth of the Global Antibody Production Market?
- What are the key challenges impacting the global Antibody Production market growth?
- What are the outcomes of the SWOT Analysis and Porter’s Five Forces Analysis conducted in the report?
Request a Sample Report on Antibody Production Market @ https://www.reportsanddata.com/sample-enquiry-form/1404
Thank you for reading our report. Do connect with us in case of any more queries about the report and its customization. Our team will ensure the report is well suited to cater to your needs.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
The Global Antibody Production Market research report offers accurate insights for the growth prospects of the Antibody Production market in the forecast years 2020-2027.
The report is an all-inclusive study of the Antibody Production market that offers the readers a better view of the current and emerging market trends through a thorough analysis of the market size, growth trends, supply and demand ratio, market share, sales network and distribution channels, and other key elements.Furthermore, the report is furnished with the current market scenario with regards to the COVID-19 pandemic.
The global public health emergency has disrupted the lives of everyone across the globe.
It has also had a substantial impact on the Antibody Production industry as global supply chains have been disrupted, and the financial scenario is tight.
The report assesses the initial and future impact of the pandemic on the market and its key segments to offer an accurate futuristic outlook for remuneration in a post-COVID-19 scenario.Get a sample copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/1404Scope of the Market Report:The report offers a holistic overview of the Antibody Production industry that offers all the essential information.
The report is formulated by extensive primary and secondary research and backed by the verified data from industry experts and professionals.
The increasing adoption of the real-time tracking technology, due to the surging integration of the internet of things (IoT) in the transportation and logistics sector, is one of the major factors fueling the demand for last mile delivery solutions across the globe.
On the other hand, the delivery-partner-centric real-time tracking technology allows businesses to get a holistic view of the efficiency of logistics.Request to Get the Sample Report: https://www.psmarketresearch.com/market-analysis/last-mile-delivery-market/report-sampleThis, in turn, inspires them to become more customer-centric.
The adoption of this technology has propelled the expansion of the e-commerce industry.
It has become imperative for both logistics service providers and e-commerce players to have a well-developed information technology (IT) infrastructure in place for enabling the efficient tracking of transactions and the movement of shipments at all times.
Besides this, the huge funding being provided to last mile delivery start-ups is also fueling the last mile delivery market advancement.Many venture capitalists and investors are making huge investments in start-ups operating in last mile logistics for expanding their businesses.
For example, Lalamove, which is an on-demand logistics provider based in Hong Kong, raised funding worth $300 million in its series D round in 2019 for expanding its operations across Asia-Pacific (APAC).
Rising incidence of contagious diseases is a major factor influencing market growth.Market Size – USD 9.72 billion in 2018, Market Growth - CAGR of 13.1 %, Market Trends –Rise in targeted immunotherapy adoption, along with an increase in R investment of biotechnology and pharmaceutical companies The Antibody Production market is expected to reach USD 26.16 Billion by 2026, according to a new report by Reports and Data.
This can be mainly associated with the increasing prevalence of contagious diseases globally, coupled with the expanding demand for protein therapeutics, which is promoting the development of the global market.
Also, the rise in the prevalence of infectious diseases and growth in demand for protein therapeutics is expected to spur the market growth further.
However , expensive primary antibodies will restrain the growth.Antibodies also acknowledged as immunoglobulins, are abundant Y-shaped proteins that are generated by plasma cells, and are utilized by the immune system to neutralize pathogens such as viruses and bacteria.
The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: Thermo Fisher Scientific, Inc., GeneTex, Inc., Eli Lilly and Company, Pall Corporation, Merck KGaA, , Eppendorf AG, Cellab GmbH, Abcam PLC, Sigma-Aldrich Corporation FiberCell Systems Inc.Further key findings from the report suggestThe therapeutics are incredibly useful for treating cancer, rheumatoid arthritis, and other chronic diseasesThe growing incidence of contagious diseases, coupled with expanding demand for protein therapeutics is expected to drive the growth of the market.Other factors that are responsible for the growth of the market are raised R disbursement on biotechnology and pharmaceutical companies, the patent cessation of prosperous monoclonal antibodies, therapeutic antibodies by governing authorities, and acceptance of targeted immunotherapy.The monoclonal class segment is estimated to reach USD 10.33 billion by 2026 at a CAGR of 13.2% during the forecast period.Due to the growing demand in the treatment of chronic diseases including blood disorders, cancer, and growth hormone deficiency, this segment is expected to hold a significant share during the forecast period.This downstream procedure includes the application of accurate, highly sophisticated, and effective products that include chromatography instruments & resins.The potency of cell cultures has increased over the past decade, leading to process optimization and improved yield.Apart from leveling up the process and cost-effectiveness, decrease in time required during the development of processes is being practiced by several players.The downstream process segment is estimated to reach USD 9.37 billion by 2026.The upstream process is expected to reach USD 8.35 billion by 2026 at a CAGR of 13.1% during the forecast period.The pharmaceutical and biotechnology companies of the end user segment is estimated to reach USD 10.15 billion by 2026.Due to the massive production of therapeutic antibodies and high R investment by companies for drug improvement, this segment is expected to grow significantly during the forecast period.Research Institutes of the end user segment is estimated to reach USD 7.90 billion by 2026 at the highest CAGR of 13.2% during the forecast period.The market in APAC is anticipated to be the fastest growing region with the highest CAGR of 13.2% during the forecast period, due to the rapidly evolving biotechnology industries in this region.For the purpose of this study, Reports and Data have segmented the global Antibody production market on the basis of Class, End-User, Process and Region: Class Outlook (Revenue, USD Million; 2016-2026)Monoclonal antibodiesMurineChimericHumanizedPolyclonal AntibodiesEnd User Outlook (Revenue, USD Million; 2016-2026)Pharmaceutical & Biotechnology CompaniesDiagnostic LaboratoriesResearch InstitutesProcess Outlook (Revenue, USD Million; 2016-2026)Upstream ProcessingDownstream ProcessingBrowse Complete Report “Antibody Production Market” @ https://www.reportsanddata.com/report-detail/antibody-production-marketThe report further segments the market on the basis of key regions of the world and offers an assessment of the production and manufacturing capacity, import and export, production and consumption patterns, supply and demand ratio, and the presence of key players in each region.
In-depth regional analysis covers: North AmericaU.S.CanadaMexicoEuropeGermanyU.K.FranceBENELUXRest of EuropeAsia PacificChinaJapanSouth KoreaRest of APACLatin AmericaBrazilRest of LATAMMiddle East & AfricaSaudi ArabiaA.E.Rest of MEAThe report includes primary and subjective research with a comprehensive study examined and validated by industry professionals and experts.
The Global Antibody Production Market report encompasses vital information about the Antibody Production market that offers valuable insights about the dynamics of the Antibody Production market to the readers and businesses.
The report presents key statistical data about the Antibody Production market for the forecast timeline of 2020-2026, covering historical analysis, demands and supply dynamics, current and emerging trends, and revenue estimations.
The report consists of total market insight based on the company, major countries, and applications and types in the competitive market.
The report strives to provide an accurate estimation of the market trends for the Antibody Production market from the year 2020 to the year 2027.
The research report consists of a complete market analysis, including financial standing, revenue estimation, limitations, and dynamics that might affect the market.The report is generated according to the latest economic landscape in tune with the COVID-19 crisis.
The pandemic has affected the global economic scenario, and the report provides details about its impact on the overall industry.
Global Antibody Production Market is expected to grow at a CAGR of 14.2% to reach US$ 16.32 billion in 2024.
The increasing focus of biopharmaceutical & biotechnology companies to produce antibody therapeutics is a major factor driving the growth.
The Global Antibody Production Market is driven by the factor including the presence of many large biotechnology and biopharmaceutical firms in this region.
In addition, the highly developed healthcare & research infrastructure and increased focus on drug discovery in North America have fuelled the regional Global Antibody Production Market growth.
There are many biopharmaceutical and clinical research organizations companies, which are targeting Asian countries, such as China & India for drug discovery and development.
The presence of less stringent regulations for antibodies development & production, vast genome pool, and developing healthcare infrastructure in this region are some of the major factors contributing to the growth of the sector in this region.
